MedTrace Logo

Arterial Elasticity: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)

NCT01776151 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 337

Last updated 2023-03-21

No results posted yet for this study

Summary

The purpose of this study is to find out if starting anti-retroviral therapy (ART) above 500 cluster-of-differentiation-4 (CD4)+ cells/milliliter (mL) ('early ART group') is better at reducing the stiffness of arteries than waiting to start ART until the CD4+ drops below 350 cells/mL ('deferred ART group'). Artery stiffness has been associated with an increased risk of cardiovascular (heart) disease, and could be useful as an earlier indicator of heart disease. In this study, the stiffness of arteries will be measured at study entry, months 4, 8, 12, and annually thereafter, using a tonometer on the participant's forearm.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Jason V Baker, MD · University of Minnesota

  • Daniel Duprez, MD, PhD · University of Minnesota

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-15
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01776151 on ClinicalTrials.gov